[Click eStock] "Kolon TissueGene, Value of Knee Osteoarthritis Treatment"

On the 21st, Korea Investment & Securities analyzed that the value of TG-C (formerly known as Invossa) of Kolon TissueGene could reach 8 trillion KRW. They set the target stock price at 100,000 KRW.

Researcher Wi Haeju of Korea Investment & Securities explained, "Osteoarthritis (OA) has many patients but no approved treatments," adding, "In the United States, at least 19% of adults over 45 suffer from knee OA."

He continued, "Due to the nature of the disease, once cartilage is damaged, it does not recover, so it inevitably worsens progressively," and "More than 11 pipelines, including TG-C, have undergone late-stage clinical trials, but TG-C is the only pipeline that has secured positive clinical results."

He analyzed, "TG-C is expected to obtain FDA approval as a knee OA treatment in 2028 and then expand to a disease-modifying osteoarthritis drug (DMOAD) by 2032," adding, "The Phase 3 clinical trial goals of pain reduction and joint function improvement have already been achieved." Furthermore, he said, "The likelihood of approval as an OA treatment is high," and "To expand to a DMOAD, proving cartilage regeneration effects is key."

Researcher Wi predicted, "Applying favorable analysis methods to reveal TG-C's cartilage regeneration effects, increasing the number of patients, and extending the observation period can raise the chances of success," and "The long-term follow-up clinical results to be released at the end of next month will heighten expectations for DMOAD approval."

This content was produced with the assistance of AI translation services.